p53 and MDM2 are both degraded by the ubiquitinproteasome pathway. MDM2 binds p53 and promotes its rapid degradation. MDM2 is an E3 ligase that activates self and p53 ubiquitylation. Moreover, MDM2 nuclearcytoplasmic shuttling contributes to p53 degradation in the cytoplasm. We have identi®ed a new region of MDM2 which regulates the stability of both p53 and MDM2. The ®rst 50 amino-acids of the MDM2 acidic domain (222 ± 272) contribute to MDM2 and MDM2-mediated p53 degradation by a mechanism which is independent of either MDM2 E3-ligase activity or MDM2 nucleo-cytoplasmic shuttling. The transcriptional coactivator p300 could have been involved, since it binds to the MDM2 acidic domain. However, we found that p300 stabilises MDM2, even in absence of an intact acidic domain, indicating that the MDM2 acidic region contributes to proteolysis independently of p300. We propose that the MDM2 acidic domain is required for unbiquitylated MDM2 and p53 to be degraded by cytoplasmic proteasomes. Oncogene (2001) 20, 1267 ± 1275.
Introduction
Stresses such as DNA damage, hypoxia or ribonucleotide depletion stabilise and activate the tumour suppressor p53, resulting in growth arrest or apoptosis that prevent genetic instability and tumour development (Kastan et al., 1991; Maltzman and Czyzyk, 1984; Nelson and Kastan, 1994) . p53 is inactivated in many human cancers (Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine, 1997) . p53 is a transcription factor that regulates genes implicated in growth arrest (e.g., the cyclin-dependent kinase inhibitor p21), apoptosis (e.g. Bax) (Yu et al., 1999; Zhao et al., 2000) , and auto-regulation (MDM2) (Barak et al., 1993) . MDM2 inhibits p53 by binding to its transactivation domain, thereby blocking interactions with transcription factors (Chen et al., 1993; Momand et al., 1992; Oliner et al., 1993) , and targeting p53 for degradation (Haupt et al., 1997; Kubbutat et al., 1997) . The p53-MDM2 autoregulatory feedback loop is vital, since the early embryonic lethality of mdm2-de®cient mice is rescued in a p53 null background (Jones et al., 1995; Montes de Oca Luna et al., 1995) . In nonstressed cells, MDM2 maintains p53 at low levels, which allows cell growth (Blaydes and WynfordThomas, 1998; Wasylyk et al., 1999) . In 5 ± 10% of human tumours, over-expression of MDM2 inactivates p53 (Juven-Gershon and Oren, 1999) . In culture, MDM2 expression confers oncogenic properties to ®broblasts (Fakharzadeh et al., 1991) and accelerates cell cycle progression at the G1/S transition by inhibiting endogenous p53 (Argentini et al., 2000) . In mice, targeted expression of MDM2 to the basal layer of the skin accelerates cell proliferation and enhances both chemically-induced papilloma formation and spontaneous development of pre-malignant lesions in a p53 dependent manner (Ganguli et al., 2000) .
p53 and MDM2 are degraded by the ubiquitin proteasome pathway (Chang et al., 1998; Chowdary et al., 1994; Maki et al., 1996) . MDM2 binds p53 and induces its degradation in the cytoplasm through the ubiquitin proteasome pathway (Haupt et al., 1997) . Both MDM2 and p53 contain nuclear export signals (NES) (Roth et al., 1998; Stommel et al., 1999) . Initial studies indicated that the NES of MDM2 is essential for p53 degradation (Roth et al., 1998; Tao and Levine, 1999) , whereas recent data suggest that it is dispensable, and that the NES of p53 and the MDM2 RING ®nger domain are necessary (Boyd et al., 2000b; Geyer et al., 2000) . Other regions of p53 and MDM2 are required for MDM2-mediated p53 degradation. In p53 these include the ®rst 42 amino acids that bind MDM2 (Haupt et al., 1997) , the oligomerization domain (Maki, 1999) , the C terminus (Kubbutat et al., 1998) and a sequence in the proline-rich domain (Gu et al., 2000) that is also implicated in JNK-induced degradation (Fuchs et al., 1998) . In MDM2 they are the Nterminal domain, which interacts with p53 (Haupt et al., 1997; Kubbutat et al., 1997) , the C-terminal RING ®nger domain, which is essential for E3 ligase activity (Argentini et al., 2000; Fang et al., 2000; Honda et al., 1997; Honda and Yasuda, 2000) , and a large central region, including both the acidic and the Zn ®nger domains, whose function in the regulation of p53 degradation is unknown (Kubbutat et al., 1999) .
We studied the contribution of the MDM2 acidic domain to the regulation of MDM2-mediated p53 degradation. Two tumour suppressors, ARF and Rb, interact with the MDM2 acidic domain and stabilise p53 (Hsieh et al., 1999; Pomerantz et al., 1998; Sherr, 1998; Zhang et al., 1998) . In contrast, binding of the transcriptional coactivator p300 to the acidic region stimulates MDM2-mediated p53 degradation (Grossman et al., 1998) . There are other proteins that bind to the MDM2 internal region and that could regulate p53 and MDM2 turnover, including the ribosomal protein L5 (Elenbaas et al., 1996; Marechal et al., 1994) , TBP (Leveillard and Wasylyk, 1997) , and the recently identi®ed MTBP (Boyd et al., 2000a) . We found that a deletion in the MDM2 acidic domain (amino-acids 222 ± 272), which abolishes the interaction with TBP (Leveillard and Wasylyk, 1997) , stabilises both MDM2 and p53 in dierent cell lines, without aecting MDM2-E3 ubiquitin-protein ligase activity or MDM2 nuclear-cytoplasmic shuttling. Our data indicate that unbiquitylation and nuclear export are not sucient for degradation of MDM2 or p53. We proposed that MDM2 is involved in a new regulatory step which is essential for MDM2 and p53 turnover.
Results
The acidic domain of MDM2 contributes to MDM2-induced p53 degradation
We investigated whether alteration of the MDM2 acidic region aects p53 stability, using DAD, which lacks part of the acidic domain (D222 ± 272) ( Figure  1a) . DR, which lacks the RING domain (D435 ± 489), was used as a control. We cotransfected the p53-negative cell line SCC9 with expression vectors for p53 (pCMVp53) and wild type or mutant MDM2 (pxjMDM2, pxjDR or pxjDAD), and measured protein levels by Western blotting. As expected, MDM2 induced degradation of exogenous p53 in a proteasome-dependent manner ( Figure 1b , bottom panel; compare lanes without and with the proteasome inhibitor, 7LLnl/+LLnL). In contrast, DAD and DR did not cause p53 degradation. The MDM2 mutants were eciently expressed (Figure 1b, upper panel) . We also analysed the eect of DAD on endogenous wild type p53 in RPMI 2650 cells (Argentini et al., 2000) . Transfected cells were selected by the Hook TM system (Invitrogen). p53 levels were decreased by expression of MDM2, but not by DAD (Figure 1c , middle panel). In fact, DAD stabilised p53, possibly by acting as a trans-dominant mutant, similar to DR (Argentini et al., 2000) . Control Western blots showed that MDM2 and DAD were eciently expressed (upper panel) The MDM2 acidic region does not contribute to the MDM2 E3 ligase activity MDM2 is a ubiquitin protein ligase (E3) (Argentini et al., 2000; Fang et al., 2000; Honda and Yasuda, 2000) . We investigated if the acidic domain of MDM2 regulates its E3 ligase activity by analysing ubiquitylation in vivo. To study MDM2 self-ubiquitylation, RPM 12650 cells were cotransfected with expression vectors for HA-tagged ubiquitin and either MDM2, DR or DAD. MDM2 and the mutants were immunoprecipitated and HA-tagged poly-ubiquitylated proteins were detected by Western blotting. We found that MDM2 and DAD were highly ubiquitylated, whereas DR was not ( Figure 2a , upper panel). The dierent migration of the HA-tagged poly-ubiquitylated forms of MDM2 and the DAD mutant is expected, because of the dierent molecular weights of the two proteins. Similar amounts of MDM2 and the mutants were immunoprecipitated, as shown by Western blotting for MDM2 ( Figure 2a , bottom panel). To study p53 ubiquitylation induced by MDM2, SCC9 cells were cotransfected with expression vectors for p53 and MDM2, DR or DAD. Poly-ubiquitylated forms of p53 were detected by Western-blotting after treatment with LLnL. Surprisingly, DAD induced p53 ubiquitylation as eciently as MDM2 (Figure 2b, upper panel) . As expected, the DR mutant was inactive. MDM2, DAD and DR were eciently expressed ( Figure 2b , bottom panel). These results indicate that the acidic domain contributes to the regulation of p53 stability by a mechanism that is independent of MDM2 E3 ligase activity.
The acidic domain of MDM2 is not required for nucleo-cytoplasmic shuttling
Nucleo-cytoplasmic shuttling of MDM2 could be required for p53 degradation (Freedman and Roth et al., 1998; Tao and Levine, 1999) . To investigate whether the DAD mutation aects nucleocytoplasmic shuttling, we used the heterocaryon assay. We constructed, as a control, a NES mutated mouse MDM2, NES m , with two leucine to alanine substitutions in conserved amino acids that are crucial for HDM2 nuclear export ( Figure 3 ) (Roth et al., 1998) . MDM2-transfected mouse NIH3T3 cells were fused with human SAOS-2 cells and 50 heterocaryons containing at least one transfected NIH3T3 nucleus and a SAOS-2 nucleus were observed. Nucleocytoplasmic shuttling was expressed as the percentage of heterocaryons containing at least one MDM2-positive SAOS-2 nucleus (Table 1 ) . MDM2 was found to shuttle in 90% of the heterocaryons, whereas NES m shuttled in 60%. The DR mutation also inhibited MDM2 nucleo-cytoplasmic shuttling (65% against 90%) in agreement with recent reports (Boyd et al., 2000b; Geyer et al., 2000) . The DAD mutant was able to shuttle almost as eciently as MDM2 (80% against 90%). Leptomycin B treatment eciently decreased MDM2, DAD, NES m and DR nucleo-cytoplasmic shuttling, indicating that all the MDM2 mutants shuttle, at least in part, via the CRM-1-dependent nucleo-cytoplasmic export pathway (Table 1 ) .
We then investigated whether the 30% decrease between MDM2 and NES m in the eciency of MDM2 nucleo-cytoplasmic shuttling (Table 1 ) modi®es MDM2 E3 ligase activity of MDM2-induced p53 degradation. Firstly, RPMI 2650 cells were cotransfected with the MDM2 and HA-tagged ubiquitin expression vectors, and MDM2 self-ubiquitylation was analysed as described above. We found that NES m was as eciently ubiquitylated as MDM2 and DAD ( Figure  4a , upper panel). The apparent higher poly-ubiquitylation of DAD is due to the greater amount of immunoprecipitate ( Figure 4a, bottom panel) . Secondly, SCC9 cells were cotransfected with p53 and MDM2 expression vectors and p53 degradation was analysed by Western blotting. We found that NES m degrades p53 as eciently as MDM2, whereas DAD does not ( Figure  4b ). These data indicate that the 30% decrease in the eciency of MDM2 nucleo-cytoplasmic export does not alter either MDM2 E3 ligase activity or MDM2-induced p53 degradation. The DAD mutation has a much smaller eect than the NES mutation on nucleocytoplasmic shuttling (10% versus 30%). We therefore conclude that the acidic domain is required for p53 degradation by a mechanism other than MDM2 nucleo-cytoplasmic shuttling.
The acidic domain affects MDM2 stability
Both the RING ®nger domain and the internal region (amino-acids 222 ± 437) aect MDM2 stability (Kubbutat et al., 1999) . We therefore investigated whether the acidic domain regulates MDM2 stability by following rates of degradation. RPMI 2650 cells were cotransfected with expression vectors for GFP and MDM2, DAD or DR. After 24 h de novo protein synthesis was inhibited with cycloheximide, and, at dierent times, protein levels were monitored by Western blotting Figure 5 ). The absence of either the RING or the acidic domains stabilised MDM2. Four hours after the addition of cycloheximide the amount of MDM2 decreased by about 50%, whereas the levels of DAD and DR remained unchanged ( Figure 5 , upper panel). This was not a result of variations in transfection eciency or between samples, as shown by the levels of the GFP control ( Figure 5 , bottom panel). This result was highly reproducible in several independent experiments. These data show that mutation of the acidic domain stabilises MDM2.
The effects of the acidic domain on MDM2 stability is independent of p300
The transcriptional coactivator p300 binds MDM2 and p53 and accelerates MDM2-induced p53 degradation (Grossman et al., 1998) . p300 binds in vivo to part of the MDM2 acidic region (amino-acids 217 ± 246), raising the possibility that the DAD deletion decreases the activity of p300. We studied the eects of p300 expression on the stability of MDM2 and DAD. RPMI 2650 cells were cotransfected with expression vectors for GFP and MDM2 or DAD, with or without p300. MDM2 levels were monitored by Western blotting after inhibition of protein synthesis with cycloheximide. p300 co-expression had little eect on the rate of MDM2 degradation (Figure 6a, upper panel) , whereas it increased the stability of DAD (Figure 6b , upper panel, compare for example the 8 h time points). This eect was speci®c, since p300 did not signi®cantly stabilise GFP (Figure 6a,b, bottom panels) . These results show that the DAD deletion does not decrease the eect of p300, and consequently indicate that the acidic domain regulates MDM2 stability by a mechanism that does not involve p300.
Discussion
Regulation of MDM2 and p53 cellular levels is physiologically important and proteolysis of both proteins is a key mechanism controlling their functions. We have shown that the acidic domain of MDM2 aects both MDM2 and p53 degradation. Deletion of . Twenty hours after transfection, the cells were fused to human SAOS-2 cells. Two hours after the fusion, the cells were ®xed and stained with the anti-MDM2 Ab No 365. Mouse nuclei are readily distinguishable from human nuclei by their punctate¯uorescence when stained with Hoechst (Moser et al., 1975) . Fifty heterocaryons with at least one MDM2-positive mouse cell and one human cell were analysed for each transfection. Shuttling is expressed as the percentage of heterocaryons containing at least one MDM2-positive SAOS-2 nucleus. The average of two independent experiments is given the ®rst 50 amino-acids of the acidic domain inhibits degradation by a mechanism that is independent of MDM2 E3 ligase activity and MDM2 nuclearcytoplasmic shuttling. Moreover, p300 stabilises MDM2 that lacks its acidic domain, suggesting that p300 is not involved in the eect of the acidic domain.
The absence of a large internal region of MDM2 (D222 ± 437) has been previously reported to aect MDM2 and MDM2-targeted p53 turnovers (Kubbutat et al., 1999) . Our results show that within that region, the ®rst 50 residues of the MDM2 acidic domain (amino-acids 222 ± 272) regulate MDM2 and p53 stability. Preliminary results indicate that the last 30 amino-acids of the MDM2 acidic domain (amino-acids 272 ± 300) are dispensable for p53 degradation (data not shown). Nevertheless, we cannot exclude that other sequences downstream from the acidic region could also aect MDM2 and p53 stability.
MDM2 and p53 are degraded by the ubiquitinproteasome pathway (Chang et al., 1998; Chowdary et al., 1994; Maki et al., 1996) . Proteins degraded by this pathway are ®rst covalently linked to ubiquitin and then proteolysed by 26S proteasomes. Ubiquitylation involves the successive actions of the ubiquitinactivating (E1), ubiquitin-conjugating (E2), and ubiquitin-protein ligase enzymes (E3). E1 activates free ubiquitin and transfers it to an E2 enzyme. E3, by binding its substrate and the E2-activated enzyme, mediates substrate speci®city (Haas and Siepmann, 1997; Pickart, 2000) . MDM2 possess E3 ligase activity and catalyses its own and p53 ubiquitylation (Fang et al., 2000) . The MDM2 RING ®nger domain is necessary for its E3 ligase activity and, by analogy with the E3-RING ®nger ligase AO7 (Lorick et al., 1999) , it probably recruits an E2 enzyme. Structural analysis of the ZAP-70/c-Cbl/UbcH7 complex indicates that regions other than the RING domain contribute to c-Cbl E3 ligase activity (Zheng et al., 2000) . Indeed, the c-Cbl linker sequence, which is upstream from the RING domain, contacts UbcH7. Moreover, the precise spatial arrangement of the substrate (ZAP-70) and UbcH7 is apparently important for c-Cbl E3 ligase activity. Mutation of the acidic domain of MDM2 does not signi®cantly alter its E3 ligase activity, suggesting that it does not critically alter either interactions or the spatial arrangement of the E2 enzyme.
The DAD-induced pattern of poly-ubiquitylation of p53 and MDM2 could be resistant to proteolysis. E4 proteins have been recently discovered that are necessary for the elongation step of ubiquitylation (Koegl et al., 1999) . E4 activity is believed to be essential for the selective degradation of some substrates and p53 could be one of them. E4 proteins bind to the ubiquitin moieties of low-ubiquitylated substrates, raising the possibility that the acidic domain could somehow be involved in this process. The ubiquitylated forms of p53 appear to be very similar in the presence of MDM2 or DAD, indicating that the ubiquitylation patterns are the same. However, we cannot exclude that there are subtle dierences in ubiquitylation.
Aberrant subcellular localization of poly-ubiquitylated forms of MDM2 and p53 could prevent their degradation. A deletion mutant of MDM2 (D222 ± 437) has been described that is constitutively nucleolar in the absence of ARF (Lohrum et al., 2000) . This raised the possibility that DAD and the poly-ubiquitylated forms of p53 could be stocked in the nucleolus, and thus be unable to contact the proteosomal machinery. However, we found that DAD and MDM2 have identical nuclear localization patterns and are excluded from the nucleolus in RPMI 2650, SAOS-2 and NIH3T3 cells (data not shown). These data show that the DAD deletion is not sucient to expose the nucleolar signal and that constitutive nucleolar localization cannot account for the resistance to degradation.
p53 degradation occurs into the cytoplasm and some studies have shown that nuclear export of MDM2 is essential for p53 degradation (Roth et al., 1998; Tao and Levine, 1999) . We found that the DAD mutation does not aect MDM2 nuclearcytoplasmic shuttling, strongly arguing that its eects are not due to faulty subcellular localization. Surprisingly, we found that mutation of the NES and the RING ®nger only partially aect MDM2 nuclear-cytoplasmic shuttling. Moreover, the NES signal of MDM2 is dispensable for both MDM2 E3 ligase activity and p53 degradation. These data indicate that there are other sequences in MDM2 or its complex with p53 that mediate nuclear export. Furthermore, the RING ®nger somehow contributes to the eciency of nuclear export. Interestingly, these results agree with two recent studies, which show that the MDM2 RING ®nger and the p53 NES are necessary for p53 nuclear export (Boyd et al., 2000b; Geyer et al., 2000) . The current model is that nuclear Figure 5 The MDM2 acidic domain aects MDM2 stability. Kinetics of degradation of MDM2, DR and DAD. RPMI 2650 cells were transiently cotransfected with 20 mg of pxjMDM2, pxjDR or pxjDAD, and 1 mg of pxjGFP (to monitor transfection eciency). Transfected cells were incubated with cycloheximide (80 mg/ml) and then harvested at the indicated times. Whole cell extracts (10 mg) were analysed by Western blotting with Ab No 365 (that detects only exogenous mouse MDM2) and anti-GFP a b Figure 6 The eect on p300 expression on MDM2 and DAD stability. (a) Degradation of MDM2 in the presence of p300. RPMI 2650 cells were cotransfected with 1 mg of pxjGFP and 20 mg of pxjMDM2 alone or with 10 or 30 mg of p300. Transfected cells were then processed as described in Figure 5 . Whole cell extracts (10 mg) were analysed by Western blotting with anti-MDM2 and anti-GFP Abs (No 365 and Clontech monoclonal anti-GFP). (b) Degradation of DAD in the presence of p300. RPMI 2650 cells were cotransfected with 1 mg of pxjGFP and 20 mg of pxjDAD alone or with 10 or 30 mg of p300. Transfected cells were processed and analysed as described in (a) ubiquitylation of p53 and MDM2 expose both NES signals and assure ecient cytoplasmic export before proteolysis. p300 interacts with MDM2 and activates MDM2-mediated p53 degradation by an unknown mechanism (Grossman et al., 1998) . The DAD mutation (from 222 ± 272) could have decreased the eects of p300, since it overlaps the reported p300 binding-site (217 ± 246). However, we found that overexpression of p300 stabilises MDM2 lacking the acidic domain, indicating that, if the ®rst 50 residues of MDM2 acidic region need to bind to a protein to eciently activate MDM2 and p53 degradation, that protein is not p300. The mechanism of stabilization might be related to the recently observed eects of MDM2 on p300 mediated acetylation of p53 (Kibet et al., 2000) . ARF is most probably not involved in the eects we observed, since ARF binding to the acidic domain stabilises p53 (Weber et al., 2000) . If it were ARF, then the DAD deletion would be expected to destabilise p53. However, it could possibly be a negative regulator of ARF or p300. Posttransational modi®cations of the acidic domain could be necessary for MDM2 and p53 degradation. Very recently, two clusters of phosphorylation sites have been localised in the p53 binding domain and the acidic region (Hay and Meek, 2000) . Ten out of 13 serines of the acidic region are deleted in DAD, raising the possibility that phosphorylation of the acidic domain could regulate p53 stability.
Proteasomal complexes are located in both the cytoplasm and the nucleus, and there is some indication that they have unique subunit compositions (Palmer et al., 1996; Rivett, 1998; Strack et al., 1992) . MDM2 may speci®cally interact with cytoplasmic proteasomes, where p53 is speci®cally degraded. An interesting possibility is that the acidic domain is required for interactions with proteasomes. Consequently DAD and the DAD-p53 complexes are not eciently degraded because they do not interact with proteasomes, even though they are polyubiquitylated and located in the cytoplasm. The acidic domain could interact with a scaold protein that links it to the proteasome. Interestingly, several scaold proteins have been recently described, the hPLIC proteins, that may link the E3 ligases E6AP and the bTRCP with the proteasome (Kleijnen et al., 2000) . Alternatively the acidic domain of MDM2 may also directly interact with the proteasome. In yeast, Ubr1p and Ufd4p, which belong to the RING and the HECT E3 ligase families, respectively, interact physically with dierent subunits of the proteasomal 19S particle, raising the interesting possibility that E3 ligases dock their unbiquitylated substrates to the proteasome (Xie and Varshavsky, 2000) . An interesting possibility, arising from our observations, is that MDM2 associates directly or indirectly to the 26S proteasome via its acidic region. This interaction could be an additional essential step for the degradation of poly-ubiquitylated forms of both MDM2 and p53.
Materials and methods

Cell lines and plasmids
RPMI 2650, SCC9, SAOS-2 and NIH3T3 cells were obtained from American Type Culture Collection (ATCC). RPMI 2650 cells were maintained in Eagle's Minimum Essential Medium supplemented with 10% fetal calf serum (FCS) and glutamine (2 mM). SCC9 cells were maintained in Dulbecco's Minimum Essential Medium (DMEM) supplemented with 10% FCS and hydrocortisone (0.4 mg/ml). SAOS-2 and NIH3T3 cells were maintained in DMEM with 10% FCS.
The MDM2 expression vector contains the mouse MDM2 cDNA downstream from the 60-nucleotide 5' leader of bglobin in the mammalian vector pxj41 (Leveillard and Wasylyk, 1997) . The MDM2 mutants (DR and DAD) were generated by PCR, fused to the 60-nucleotide 5' leader of bglobin, cloned into pxj41 and sequenced. The MDM2 NES mutant (NES m ) was obtained by site-directed mutagenesis of pxjMDM2. In the NES m mutant the leucines in position 192 and 195 were replaced by alanines and a new Sph1 restriction site was introduced to discriminate between wild type and mutated cDNAs. The details are available on request.
pCMVp53 contains the human p53 cDNA cloned in pCMVNeoBam. psjGFP has the GFP cDNA in pxj41. p300 contains the p300 cDNA downstream from the CMV promoter. pHA-ubiquitin is a gift from D Bohmann (Treier et al., 1994) . 
Transfections
Cells were seeded and transfected 6 h later by a modi®ed calcium phosphate method (Chen and Okayama, 1987) . Fifteen hours after adding the precipitate the cells were washed with phosphate-buered saline (PBS) and incubated for 24 h in 10% FCS medium before analysis. Where indicated, 70 mM LLnL (SIGMA) was added during the last 12 h before harvesting.
Selection of transfected cells
Transfected cells were isolated by including in the transfection pHook TM -1 (which expresses a single-chain antibody (sFv) against a hapten on the surface of transfected cells) followed by binding to hapten-coated magnetic beads (Invitrogen).
Immuno-blotting
Equal amounts of total protein in cell lysates were separated by SDS-polyacrylamide gel electrophoresis. After transfer, the nitrocellulose membranes were blocked in 5% milk in PBST (PBS 16, 0.05% Tween 20) for 1 h, then incubated overnight at 48C with speci®c antibodies. After three washes in PBST, blots were incubated for 1 h with HRP-conjugated secondary antibodies (diluted 1 : 2500), followed by detection by chemiluminescence (Pierce).
Immuno-precipitation
In order to detect MDM2 and p53 ubiquitin conjugates, transfected cells were scraped into 500 ml of RIPA buer (2 mM Tris, pH 7.5, 5 mM EDTA, 150 mM NaC1, 1% NP-40, 1% deoxycholate, 0.025% SDS, 1 mM PMSF) and sonicated two times for 5 s at 10% amplitude. Two ml of either No 365 or DO1 antibodies were added. After 2 h of incubation, protein G Sepharose TM 4 Fast Flow (Amersham) was added (dilution 1 : 10) for another hour. The beads were then washed three times with RIPA buer. Immunoprecipitated proteins were separated on 8% SDS ± PAGE and immuno-blotted as described above.
Heterocaryon assay
10
6 NIH3T3 cells were transfected with the dierent MDM2 constructs as described above. Transfected-NIH3T3 and SAOS-2 cells were treated with cycloheximide (100 mg/ml) for 3 h prior to fusion, to block de novo protein synthesis. Leptomycin B was added at the same time as cycloheximide. After the cycloheximide treatment, the cells were trypsinised and 4610 5 transfected NIH3T3 were mixed with 1.5610 6 SAOS-2 cells, in presence of cycloheximide alone or cycloheximide and leptomycin B. After centrifugation, the cells were fused for 2 min with PEG 3350 (pre-warmed to 378C) and 1 ml of medium with cycloheximide was added for 10 min. After centrifugation, fused cells were plated on coverslips in the presence of cycloheximide alone or leptomycin B. Two hours later, the cells were ®xed with 3.7% formaldehyde in PBS for 15 min, followed by permeabilization with 0.2% Triton X-100 in PBS (20 min). The cells were then incubated successively with a blocking solution (0.5% BSA in PBS) for 10 min, the primary antibody No 365 (dilution 1 : 400 in blocking solution) for 1 h, PBS three washes for 5 min, Texas-Red-conjugated goat anti-rabbit secondary antibody (dilution 1 : 300 in blocking solution) for 1 h and PBS three washes for 5 min. The coverslips were incubated for 1 min in Hoechst dye (5 mg/ml in PBS), washed three times in PBS and mounted by inversion on a drop of mounting solution (80% glycerol, 20% 16PBS with 5% propylgallate) on a glass slide. Heterocaryons were analysed under a¯uorescence microscope.
